Novocure Narrows Q3 Loss to $10.4M, Turns Adjusted EBITDA Positive and Lifts Full-Year Revenue Outlook
NVCR sits 56% above its 52-week low of $9.82.
Summary
Novocure posted a Q3 net loss of $10.4M while revenue rose 16% to $193.4M and gross margin expanded to 77%. Adjusted EBITDA came in positive at $15.7M — a meaningful swing for a company still burning cash on its income statement. Research, development and clinical study expenses were $58.1M. Management also raised full-year revenue and adjusted EBITDA guidance, lifting its 2026 view to revenue of $736M-$743M from $710M-$725M and adjusted EBITDA guidance to $24M-$34M from $0M-$15M, which is the part that matters most here. The quarter follows the October 1 Japanese approval of Optune Pax for locally advanced pancreatic cancer, adding a new commercial market on top of the core glioblastoma business. The offsetting backdrop is the June TRIDENT Phase 3 miss in earlier-line glioblastoma, so growth is leaning on existing indications and the pancreatic launch.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — Novocure raised 2026 revenue guidance to $736M-$743M from $710M-$725M and adjusted EBITDA guidance to $24M-$34M from $0M-$15M.
At the time of this announcement, NVCR was trading at $15.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $9.82 to $21.45. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.